EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Issue 12 (19th July 2013)

• Record Type: Journal Article
• Authors: Duru, N; van der Goes, M C; Jacobs, J W G; Andrews, T; Boers, M; Buttgereit, F; Caeyers, N; Cutolo, M; Halliday, S; Da Silva, J A P; Kirwan, J R; Ray, D; Rovensky, J; Severijns, G; Westhovens, R; Bijlsma, J W J
• Is Part Of: Annals of the rheumatic diseases. Volume 72:Issue 12(2013)
• Page Start: 1905
• Page End: 1913
• Publication Date: 2013-07-19
• Subjects: Corticosteroids -- Autoimmune Diseases -- Treatment; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-203249
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : To develop recommendations for the management of medium to high-dose (ie, >7.5 mg but ≤100 mg prednisone equivalent daily) systemic glucocorticoid (GC) therapy in rheumatic diseases. A multidisciplinary EULAR task force was formed, including rheumatic patients. After discussing the results of a general initial search on risks of GC therapy, each participant contributed 10 propositions on key clinical topics concerning the safe use of medium to high-dose GCs. The final recommendations were selected via a Delphi consensus approach. A systematic literature search of PubMed, EMBASE and Cochrane Library was used to identify evidence concerning each of the propositions. The strength of recommendation was given according to research evidence, clinical expertise and patient preference. The 10 propositions regarded patient education and informing general practitioners, preventive measures for osteoporosis, optimal GC starting dosages, risk-benefit ratio of GC treatment, GC sparing therapy, screening for comorbidity, and monitoring for adverse effects. In general, evidence supporting the recommendations proved to be surprisingly weak. One of the recommendations was rejected, because of conflicting literature data. Nine final recommendations for the management of medium to high-dose systemic GC therapy in rheumatic diseases were selected and evaluated with their strengths of recommendations. Robust evidence was often lacking; a research agenda was created.